Follow Us

TNI BioTech, Inc., in Partnership with GB Oncology and Imaging Group LTD., signs Agreement With The Republic Of Malawi

Aug 07 2012

TNI BioTech, Inc., in Partnership with GB Oncology and Imaging Group LTD., signs Agreement With The Republic Of Malawi

West Palm Beach, Florida, and Washington DC, August 7, 2012 – TNI BioTech, Inc., (PINKSHEETS: TNIB) announced today that the company, under its joint venture agreement with GB Oncology and Imaging Group LTD, ("GBOIG") signed a letter of intent agreement to open and operate clinics for oncology and the treatment of HIV/AIDS and other infectious diseases in the Republic of Malawi, Africa.

The companies believe the clinics are an important step for TNIB as there is urgent need in Malawi for readily available, safe and effective treatments that can hopefully increase the life span and improve the quality of life of millions of HIV/AIDS and cancer patients. U.S. officials estimate about 1 in 10 Malawians is infected with HIV or has AIDS and the United Nations estimates approximately 23 million people in Sub-Saharan Africa are HIV positive. Sub-Saharan Africa accounts for only 12% of the global population, yet in 2010, 68% of all the people worldwide living with HIV resided in the Sub-Saharan Africa region. 70% of all new HIV infections are in sub-Saharan Africa and 90% of children living with HIV live in sub-Saharan Africa. Almost half of the deaths from AIDS-related illnesses in 2010 were in southern Africa.

The new government of the Republic of Malawi, under President Joyce Banda, a women's rights activist who has backed aggressive HIV prevention programs, signed an agreement with GBOIG, in partnership with TNIB, to provide treatments for HIV/AIDS, cancer and infectious diseases. TNIB, in partnership with GBOIG, seeks to deliver advanced treatments - including safer, more effective radiation therapy; new-targeted drug therapies; and minimally invasive surgical alternatives. At the same time, the clinics will support patients using TNI BioTech patented therapies to boost the immune system and improve quality of life. There are reasons for believing that an effective medical treatment already exists for preventing the HIV positive status from developing into full-blown AIDS. Low Dose Naltraxone (LDN) in clinical trials, both in the United States and Africa, has shown to be an effective immune system modulator, without significant toxic side effects, non-addicting and can be administered by a single capsule once daily at bedtime. IRT-103 ( http://www.tnibiotech.com/products ) (LDN) is also now available as a transdermal cream that is made for and is particularly effective with children suffering from a compromised immune system.

Dr. Gloria Herndon, Managing Member of GBOIG, said, "Though cultural mores change very slowly, we believe that IRT-103 (LDN) can serve to save literally millions of lives within a relatively short time at a cost of a $1.00 a day per person. This is in marked contrast to the $240 per dose for the antiretroviral drugs which must be taken several times a day, require a lot of medical supervision, and are notorious for toxic side effects and drug resistance in the patients who are fortunate enough to obtain them."

Noreen Griffin, CEO of TNIB, said, "When you understand that there are millions of victims of HIV/AIDS in Africa and only 37% of the people eligible for treatment in sub-Saharan Africa received antiretroviral drug treatment in 2009 because of economics, health personnel availability, and drug availability, we felt that something had to be done." TNIB has previously reached agreements to acquire the patents and research relating to IRT-103 (LDN), done by Dr. Bernard Bihari over the past 20 years, that demonstrate the effectiveness of this very inexpensive, non-addicting, non-invasive medication that is without significant toxic side effects.

Under the Agreement, GBOIG and TNIB expect to have the oncology and infectious disease clinic fully operational within Twelve (12) months, and hope to begin treatment for HIV patients within One Hundred Eighty (180) days of the signing of the Agreement. Under the Agreement, TNIB and GBOIG will begin by providing HIV/AIDS treatment to Twenty-Five Thousand (25,000) patients and hopefully expand to Five Hundred Thousand (500,000) within Twenty-Four (24) months.

About GB Oncology & Imaging Group LTD.

GB Oncology and Imaging Group LTD., a subsidiary of GB Energie LLC is a Washington D.C. based minority woman-owned business managed by Dr. Gloria B. Herndon. Dr. Herndon is committed to sourcing sustainable solutions in the field of health care in Africa, and has been involved since the mid 1960's on health-care related issues in Africa and, on occasion, serves as a consulting resource for the National Institutes of Health (NIH) regarding the impact of the HIV/AIDS pandemic on the insurance industry and provides other AIDS-related information when requested by the United States Department of State. Dr. Herndon is also a director of TNI BioTech, Inc.

About TNI BioTech

TNI BioTech, Inc., is a biotech company combating fatal diseases through the activation and mobilization of the body's immune system using our patented immunotherapy.

Our products and technologies are designed to harness the power of the immune system to improve the treatment and diagnosis of cancer, infections such as HIV/AIDS and autoimmune diseases. We have been developing active and adaptive forms of immunotherapies.

Our proprietary technology, therapies and patents, will be used to treat a wide range of cancers. Our most advanced clinical programs involve immunotherapy that works by isolating a patient's lymphocytes and then incubating them together with Methionine Enkephalin (MENK) in an enriching external incubation system. After incubation the patient's lymphocytes are reinfused back into the patient where they combat and destroy tumor cells.

However, even though Management considers any condition that results in altered-immune response a target for investigation, the Company will most likely pursue additional investigations for MENK as a valuable candidate in the treatment of the following:
 Autoimmune states such as rheumatoid arthritis and multiple sclerosis;
 As an adjunct to antibiotics in the treatment of infectious diseases;
 In patients undergoing chemotherapy, radiation treatments or surgery; and
 In wound healing, herpes viral infections, and in treatment for the elderly.

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS: This press release includes various "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which represent the Company's expectations or beliefs concerning future events. Statements containing expressions such as "believes," "anticipates," "intends," or "expects," used in the Company's press releases and in Disclosure Statements and Reports filed with the Over The Counter Markets through the OTC Disclosure and News Service are intended to identify forward-looking statements. All forward-looking statements involve risks and uncertainties. Although the Company believes its expectations are based upon reasonable assumptions within the bounds of its knowledge of its business and operations, there can be no assurances that actual results will not differ materially from expected results. The Company cautions that these and similar statements included in this report are further qualified by important factors that could cause actual results to differ materially from those in the forward-looking statements. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date thereof. The Company undertakes no obligation to publicly release any revisions to such forward-looking statements to reflect events or circumstances after the date hereof.

See www.tnibiotech.com for more information.

Contact: Marmel Communications, LLC
Marlin Molinaro
Phone: (702) 434-8692

Contact: Global Investment Media
Phone: 310 353 6277